同益中（688722）：增资赋能超美斯，盈利能力改善可期

Investment Rating - The report maintains a "Buy-A" rating for the company [1][4] Core Views - The company has shown significant revenue growth in Q1 2025, achieving total revenue of 253 million yuan, with year-on-year growth of 126.9% and quarter-on-quarter growth of 14.1% [2][3] - The increase in revenue is attributed to higher sales volume and the acquisition of subsidiaries [3] - The company plans to invest 150 million yuan in its subsidiary, Chaomeisi, to enhance its competitive strength and profitability, aiming for high-quality development [3] - Chaomeisi reported revenue of 68 million yuan and a net profit of 2.27 million yuan in Q1 2025, indicating potential for significant improvement compared to industry peers [3] Financial Projections - The company is projected to achieve net profits of 200 million yuan, 240 million yuan, and 290 million yuan for the years 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 28, 23, and 19 [4][6] - Revenue forecasts for the years 2025 to 2027 are 996 million yuan, 1.196 billion yuan, and 1.407 billion yuan, reflecting year-on-year growth rates of 53.3%, 20.1%, and 17.7% [6][10] - The gross profit margin is expected to stabilize around 36.4% to 37.2% over the forecast period [6][11] Market Data - As of May 12, 2025, the company's closing price was 24.99 yuan, with a year-to-date high of 26.60 yuan and a low of 9.57 yuan [7] - The total market capitalization is approximately 5.614 billion yuan, with 224 million circulating shares [7]